| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
3,070,000 |
| Market
Cap: |
12.03(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.11 - $6.25 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Business Services |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sonnet BioTherapeutics Holdings is a clinical-stage biopharmaceutical company with a proprietary technology for developing biologic medicines it refers to as FHAB (Fully Human Albumin Binding). Co. has a pipeline of therapeutic compounds focused primarily on oncology indications of unmet medical need, including SON-080, a low-dose formulation of Interleukin 6 which is in development for Chemotherapy Induced Peripheral Neuropathy; SON-1010, which is being developed for solid tumor indications, including non-small cell lung cancer and head and neck cancer, as well as for antiviral applications; and SON-1210, which is being developed for solid tumor indications, including colorectal cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
50,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-04-06 |
2025-01-03 |
2024-07-05 |
2023-07-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mcandrew Stephen J |
Chief Business OfficerOfficer |
• – – |
2025-02-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
446 |
|
-27% |
|
| Mohan Pankaj |
Chairman, President and CEO |
• • – |
2023-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
7,554 |
14,987 |
|
- |
|
| Bhatt Nailesh |
Director |
– • – |
2023-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
373 |
547 |
|
- |
|
| Rao Raghu |
Director |
– • – |
2023-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
373 |
2,356 |
|
- |
|
| Dyrness Albert D. |
Director |
– • – |
2023-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
373 |
537 |
|
- |
|
| Griffith Donald J. |
Director |
– • – |
2023-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
317 |
375 |
|
- |
|
| Cross John Harry Iii |
Chief Financial Officer |
• – – |
2023-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,452 |
1,588 |
|
- |
|
| Cini John K. |
Chief Scientific Officer |
• – – |
2023-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,888 |
2,116 |
|
- |
|
| Kenney Richard T |
Chief Medical Officer |
• – – |
2023-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,271 |
1,374 |
|
- |
|
| Mcneill Lori |
Director |
– • – |
2023-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
373 |
394 |
|
- |
|
| Dexter Susan |
Chief Technical Officer |
• – – |
2023-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,452 |
1,643 |
|
- |
|
| Mohan Pankaj |
Chairman, President and CEO |
• • – |
2023-10-27 |
4 |
B |
$0.00 |
$0 |
D/D |
34,375 |
59,526 |
2.73 |
- |
|
| Rao Raghu |
Director |
– • – |
2023-10-27 |
4 |
B |
$0.00 |
$0 |
D/D |
15,625 |
16,813 |
2.31 |
- |
|
| Markey John |
10% Owner |
– – • |
2023-08-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
186,430 |
|
- |
|
| Dexter Susan |
Chief Technical Officer |
• – – |
2023-06-14 |
4 |
B |
$0.70 |
$7,000 |
D/D |
10,000 |
33,667 |
2.74 |
- |
|
| Dyrness Albert D. |
Director |
– • – |
2023-05-30 |
4 |
B |
$0.47 |
$10,883 |
D/D |
23,255 |
28,962 |
2.39 |
- |
|
| Bhatt Nailesh |
Director |
– • – |
2023-05-17 |
4 |
B |
$0.23 |
$5,800 |
D/D |
25,000 |
30,733 |
2.39 |
- |
|
| Mohan Pankaj |
Chairman, President and CEO |
• • – |
2023-05-15 |
4 |
B |
$0.22 |
$82,867 |
D/D |
371,600 |
553,331 |
2.81 |
- |
|
| Mohan Pankaj |
Chairman, President and CEO |
• • – |
2023-03-15 |
4 |
B |
$0.59 |
$35,100 |
D/D |
60,000 |
181,731 |
2.81 |
- |
|
| Cross John Harry Iii |
Chief Financial Officer |
• – – |
2023-02-06 |
4 |
D |
$1.06 |
$2,078 |
D/D |
(1,960) |
23,927 |
|
- |
|
| Griffith Donald J. |
Director |
– • – |
2023-02-06 |
4 |
D |
$1.04 |
$518 |
D/D |
(497) |
10,301 |
|
- |
|
| Kenney Richard T |
Chief Medical Officer |
• – – |
2023-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
14,627 |
18,198 |
|
- |
|
| Kenney Richard T |
Chief Medical Officer |
• – – |
2023-01-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,627) |
3,571 |
|
- |
|
| Cini John K. |
Chief Scientific Officer |
• – – |
2023-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
18,551 |
40,271 |
|
- |
|
| Cini John K. |
Chief Scientific Officer |
• – – |
2023-01-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(18,551) |
21,720 |
|
- |
|
169 Records found
|
|
Page 1 of 7 |
|
|
0.23 (5.54%) 
